Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3845958

Nc1scc[n+]1CC(=O)c1ccccc1.[Cl-]

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.54
ALDH1A1 P00352 7/20 0.51
POLB P06746 1/20 0.51
KMT2A Q03164 7/20 0.50
MEN1 O00255 4/20 0.50
SMN1; SMN2 Q16637 5/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
RECQL P46063 2/20 0.43
PABPC1 P11940 1/20 0.43
ATM Q13315 1/20 0.43
KDM4E B2RXH2 5/20 0.43
HTT P42858 3/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
ALPG P10696 1/20 0.41
MAPT P10636 2/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
CES1 P23141 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18745980 0.98 RAB9A (0.55) RAB9AALDH1A1POLBKMT2AMEN1
SCHEMBL12935587 0.83 PABPC1 (0.53) RAB9AALDH1A1POLBKMT2AMEN1
SCHEMBL23752059 0.79 ALDH1A1 (0.53) RAB9AALDH1A1POLBKMT2AMEN1
Hydrochloric Acid SCHEMBL7421854 0.79 ALDH1A1 (0.49) RAB9AALDH1A1POLBKMT2AMEN1
Bromide SCHEMBL6074531 0.78 ALDH1A1 (0.55) RAB9AALDH1A1POLBKMT2AMEN1
SCHEMBL19221769 0.78 GABRA5 (0.35) RAB9AALDH1A1MAPTMAPK1
Hydrochloric Acid SCHEMBL3844254 0.76 ALDH1A1 (0.46) RAB9AALDH1A1POLBKMT2AMEN1
Bromide SCHEMBL6009338 0.75 KMT2A (0.51) RAB9AALDH1A1POLBKMT2AMEN1
Bromide SCHEMBL6009336 0.74 ALDH1A1 (0.50) RAB9AALDH1A1POLBKMT2AMEN1
Bromide SCHEMBL4937075 0.74 LTA4H (0.51) RAB9AALDH1A1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2085086-A2 Method for treating congestive heart failure or diabetic nephropathy Synvista Therapeutics, Inc. (US) 2009-08-05 EP disclosed
US-20090124674-A1 Method for treating congestive heart failure SYNVISTA THERAPEUTICS, INC. (US) 2009-05-14 US disclosed
US-20090124673-A1 Method for treating diabetic nephropathy SYNVISTA THERAPEUTICS , INC. (US) 2009-05-14 US disclosed
US-7432254-B2 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. (US) 2008-10-07 US disclosed
EP-1353669-B1 METHOD FOR TREATING GLAUCOMA ALTEON INC (US) 2007-08-15 EP disclosed
US-7166625-B2 Method for treating fibrotic diseases and other indications ALTEON, INC. (US) 2007-01-23 US disclosed
EP-1305024-A4 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON INC (US) 2006-03-22 EP disclosed
EP-1353669-A4 METHOD FOR TREATING GLAUCOMA IB ALTEON INC (US) 2005-10-19 EP disclosed
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE SYNVISTA THERAPEUTICS, INC. 2004-11-25 US disclosed
EP-1353669-A1 METHOD FOR TREATING GLAUCOMA IB Alteon, Inc. (US) 2003-10-22 EP disclosed
EP-1305024-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC Alteon, Inc. (US) 2003-05-02 EP disclosed
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID SYNVISTA THERAPEUTICS, INC. 2002-11-28 US disclosed
US-20020160993-A1 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. 2002-10-31 US disclosed
WO-2002053158-A1 METHOD FOR TREATING GLAUCOMA IB ALTEON, INC. (US) 2002-07-11 WO disclosed
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC ALTEON, INC. 2002-06-06 US disclosed
WO-2002007725-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON, INC. (US) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE MMP1, COL1A1, COL2A1 RAB9A 2851/4885ALDH1A1 175/4885POLB 2072/4885
US-20020160993-A1 Method for treating glaucoma IC CHAT, MYOC, GAP43 RAB9A 2313/4885ALDH1A1 366/4885POLB 3857/4885
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC MMP1, COL1A1, COL2A1 RAB9A 3660/4885ALDH1A1 204/4885POLB 2130/4885
US-20090124673-A1 Method for treating diabetic nephropathy REN, SLC5A2, SLC5A1 RAB9A 3397/4885ALDH1A1 402/4885POLB 3981/4885
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID MMP1, COL1A1, COL2A1 RAB9A 3572/4885ALDH1A1 261/4885POLB 1901/4885
US-20090124674-A1 Method for treating congestive heart failure TNNI3, TNNT2, FABP3 RAB9A 4074/4885ALDH1A1 448/4885POLB 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.